aspirin and Embryopathies studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

Excerpt	Relevance	Reference
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy."	9.01	[Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019)
"Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy."	7.69	Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996)
"Indications for aspirin during pregnancy are a matter of debate and there is a recent trend to an extended prescription and an overuse of aspirin in pregnancy."	5.01	[Aspirin and preeclampsia]. ( Atallah, A; Doret-Dion, M; Gaucherand, P; Goffinet, F; Lecarpentier, E; Tsatsaris, V, 2019)
"The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders."	3.77	Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011)
"The prevention of preeclampsia currently relies on low-dose aspirin started at the beginning of pregnancy."	3.72	[Prevention of preeclampsia]. ( Desvaux, D; Haddad, B, 2003)
"Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy."	3.69	Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996)
"Over-the-counter antipyretics (acetaminophen, aspirin, ibuprofen) and/or analgesics (acetaminophen, aspirin, diclofenac, ibuprofen, naproxen) are relatively safe for adults."	2.48	[Developmental toxicity of the over-the-counter analgetics and antypiretics]. ( Burdan, F; Cendrowska-Pinkosz, M; Dworzańska, A; Dworzański, W; Kubiatowski, T; Starosławska, E; Szumiło, J; Urbańczyk-Zawadzka, M, 2012)
"If diagnosed and treated early in pregnancy with low-dose aspirin and subcutaneous heparin the outlook for a successful pregnancy is much improved."	2.41	A literature review on the antiphospholipid syndrome and the effect on childbearing. ( Vials, JM, 2001)
"We estimated the proportion of miscarriage to be almost doubled, whereas there was no increased risk of congenital abnormalities or prematurity in women exposed to a drug overdose compared with the background population."	1.31	Pregnancy outcome after suicide attempt by drug use: a Danish population-based study. ( Flint, C; Larsen, H; Nielsen, GL; Olsen, J; Sørensen, HT, 2002)

Research

Studies (21)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

Fetal Outcome 4 - Incidence of Fetal Loss

Fetal Outcome 5 - Incidence of Spontaneous Abortion

Fetal Outcome 6 - Incidence of All Stillbirth

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (28.57)	18.7374
1990's	5 (23.81)	18.2507
2000's	7 (33.33)	29.6817
2010's	3 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Atallah, A	1
Lecarpentier, E	1
Goffinet, F	2
Gaucherand, P	1
Doret-Dion, M	1
Tsatsaris, V	1
Bakhti, A	1
Vaiman, D	1
Burdan, F	1
Starosławska, E	1
Szumiło, J	1
Dworzańska, A	1
Dworzański, W	1
Kubiatowski, T	1
Cendrowska-Pinkosz, M	1
Urbańczyk-Zawadzka, M	1
PETROV-MASLAKOV, MA	1
Desvaux, D	1
Haddad, B	1
Nitsch, P	1
Breuer, J	1
Geipel, A	1
Bartmann, P	1
Gembruch, U	1
Heep, A	1
Iwashita, T	1
Fujitani, M	1
Yamamoto, Y	1
Katsurada, T	1
Yoshida, Y	1
Aguilera, C	1
Agustí, A	1
Srivastava, AR	1
Modi, P	1
Sahi, S	1
Niwariya, Y	1
Singh, H	1
Banerjee, A	1
Soller, RW	1
Stander, H	1
Van Marter, LJ	1
Leviton, A	1
Allred, EN	1
Pagano, M	1
Sullivan, KF	1
Cohen, A	1
Epstein, MF	1
Bréart, G	1
Uzan, S	1
Wakatsuki, A	1
Izumiya, C	1
Okatani, Y	1
Sagara, Y	1
Vials, JM	1
Flint, C	1
Larsen, H	1
Nielsen, GL	1
Olsen, J	1
Sørensen, HT	1
Ginsberg, JS	1
Hirsh, J	1
Raub, W	1
Lubbe, WF	1
Liggins, GC	1
Wilson, JG	1
Fisch, L	1
Warkany, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]		11,976 participants (Actual)	Interventional	2016-03-23	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Intervention Arm	189
Placebo Arm	230

Intervention	Participants (Count of Participants)
Intervention Arm	1078
Placebo Arm	1153

Intervention	Participants (Count of Participants)
Intervention Arm	78
Placebo Arm	101

Intervention	Participants (Count of Participants)
Intervention Arm	303
Placebo Arm	353

Intervention	Participants (Count of Participants)
Intervention Arm	134
Placebo Arm	152

Intervention	Participants (Count of Participants)
Intervention Arm	141
Placebo Arm	166

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

Incidence of Hypertensive Disorders of Pregnancy

Intervention	Participants (Count of Participants)
Intervention Arm	42
Placebo Arm	30

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

Incidence of Perinatal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	352
Placebo Arm	325

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Incidence of Preterm Birth

Intervention	Participants (Count of Participants)
Intervention Arm	264
Placebo Arm	309

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

Incidence of Small for Gestational Age (SGA)

Intervention	Participants (Count of Participants)
Intervention Arm	668
Placebo Arm	754

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 1 - Incidence of Vaginal Bleeding

Intervention	Participants (Count of Participants)
Intervention Arm	1506
Placebo Arm	1564

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	214
Placebo Arm	246

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

Intervention	Participants (Count of Participants)
Intervention Arm	26
Placebo Arm	25

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 4 - Incidence of Maternal Mortality

Intervention	Participants (Count of Participants)
Intervention Arm	54
Placebo Arm	43

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 5 - Incidence of Late Abortion

Intervention	Participants (Count of Participants)
Intervention Arm	9
Placebo Arm	12

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Maternal Outcome 6 - Change in Maternal Hemoglobin

Intervention	Participants (Count of Participants)
Intervention Arm	23
Placebo Arm	30

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Intervention	Participants (Count of Participants)
Intervention Arm	290
Placebo Arm	333

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

Article	Year
[Aspirin and preeclampsia]. Presse medicale (Paris, France : 1983), 2019, Volume: 48, Issue:1 Pt 1 Topics: Aspirin; Chronobiology Phenomena; Contraindications, Drug; Cyclooxygenase Inhibitors; Drug Utilizati	2019
[Developmental toxicity of the over-the-counter analgetics and antypiretics]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:192 Topics: Adult; Analgesics; Antipyretics; Aspirin; Female; Fetal Diseases; Humans; Infant, Newborn; Infant, N	2012
Anticoagulation for pregnant patients with mechanical heart valves. Annals of cardiac anaesthesia, 2007, Volume: 10, Issue:2 Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Drug Administration Schedule; Female; Fetal Diseases	2007
A literature review on the antiphospholipid syndrome and the effect on childbearing. Midwifery, 2001, Volume: 17, Issue:2 Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Embolism; Female; Fetal Death; Fetal Diseases; F	2001
Use of antithrombotic agents during pregnancy. Chest, 1992, Volume: 102, Issue:4 Suppl Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Diseases; Hemorrhage; Humans; Oste	1992
Lupus anticoagulant and pregnancy. American journal of obstetrics and gynecology, 1985, Oct-01, Volume: 153, Issue:3 Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt	1985
Present status of drugs as teratogens in man. Teratology, 1973, Volume: 7, Issue:1 Topics: Abnormalities, Drug-Induced; Alkylating Agents; Anti-Bacterial Agents; Anticonvulsants; Antiemetics;	1973

Article	Year
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:10 Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal	2011
[PRENATAL PROTECTION OF THE FETUS AND PROBLEMS OF DRUG THERAPY IN PREGNANCY]. Sovetskaia meditsina, 1964, Volume: 28 Topics: Adrenal Cortex Hormones; Aminopyrine; Anti-Bacterial Agents; Aspirin; Drug Therapy; Female; Fetal Di	1964
[Prevention of preeclampsia]. Presse medicale (Paris, France : 1983), 2003, Oct-11, Volume: 32, Issue:33 Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal Diseas	2003
Dilatation of the abdominal umbilical vein is associated with increased risk of thrombotic complications. Journal of perinatal medicine, 2006, Volume: 34, Issue:3 Topics: Abdomen; Adult; Aspirin; Dilatation, Pathologic; Female; Fetal Diseases; Fibrinolytic Agents; Hepari	2006
Interferon-alfa treatment of essential thrombocythemia during pregnancy. Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:20 Topics: Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Diseases; Humans; Immunolog	2006
[Low dose of aspirin during pregnancy]. Medicina clinica, 2007, Jan-13, Volume: 128, Issue:1 Topics: Abnormalities, Drug-Induced; Abortion, Habitual; Abortion, Spontaneous; Adult; Animals; Anti-Inflamm	2007
Maternal drug exposure and perinatal intracranial hemorrhage. Obstetrics and gynecology, 1981, Volume: 58, Issue:6 Topics: Aspirin; Cerebral Hemorrhage; Female; Fetal Diseases; Humans; Infant, Newborn; Infant, Newborn, Dise	1981
Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. Pediatrics, 1996, Volume: 97, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cocaine; Confounding	1996
ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. British journal of obstetrics and gynaecology, 1996, Volume: 103, Issue:7 Topics: Aspirin; Female; Fetal Diseases; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Compl	1996
Oxidative damage in fetal rat brain induced by ischemia and subsequent reperfusion. Relation to arachidonic acid peroxidation. Biology of the neonate, 1999, Volume: 76, Issue:2 Topics: Animals; Arachidonic Acid; Aspirin; Brain; Cyclooxygenase Inhibitors; Disease Models, Animal; Female	1999
Pregnancy outcome after suicide attempt by drug use: a Danish population-based study. Acta obstetricia et gynecologica Scandinavica, 2002, Volume: 81, Issue:6 Topics: Abortion, Spontaneous; Acetaminophen; Adolescent; Adult; Aspirin; Child; Child, Preschool; Denmark;	2002
From the National Institutes of Health. JAMA, 1990, Mar-02, Volume: 263, Issue:9 Topics: Aspirin; Breast Neoplasms; Female; Fetal Diseases; Heart Defects, Congenital; Humans; Immunotherapy;	1990
The selective and differential vulnerability of the auditory system. In: Sensorineural hearing loss. Ciba Foundation symposium, 1970 Topics: Aspirin; Auditory Pathways; Central Nervous System; Cochlea; Deafness; Diseases in Twins; Ear; Facia	1970
Experimental teratology and pediatrics. Paediatria Universitatis Tokyo, 1970, Volume: 18 Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Congenital Abnormalities; Female; Fetal Diseases; Mam	1970

aspirin and Embryopathies